DIFFERENCES IN HEALTH CARE UTILIZATION AND ASSOCIATED COSTS BETWEEN PATIENTS PRESCRIBED VERSUS NOT PRESCRIBED OPIOIDS DURING AN INPATIENT OR EMERGENCY DEPARTMENT VISIT
Author(s)
Xie L1, Joshi AV2, Harnett J2, Mardekian J2, Schaaf D2, Shah N3, Baser O41STATinMED Research, Ann Arbor, MI, USA, 2Pfizer, Inc., New York, NY, USA, 3Mayo Clinic, Rochester, MN, USA, 4STATinMED Research/The University of Michigan, Ann Arbor, MI, USA
OBJECTIVES: Compare health care resource utilization (HCRU) and costs between patients prescribed opioids versus those who were not during emergency department (ED) or inpatient visits. METHODS: Patients with ED/inpatient visits were selected from the MarketScan Commercial and Medicare Supplemental Database linked with the Marketscan Hospital Discharge Database (1/12007–9/30/2009). Patients prescribed opioids in the ED/inpatient setting were assigned to the ‘Opioid Patient (RxOP)’ cohort. The first prescription date was the index date. Among patients not prescribed opioids, the ‘Non-Opioid Patient (NoRxOP)’ cohort, a random date between the first ED/inpatient admission and 30SEPT2009 served as the index date. Additional inclusion criteria were: age older than 12 years at index date, and 12 months of continuous enrollment before and after the index date. Patients with opioid prescriptions during the pre-index period were excluded. Differences in patients’ age, gender, geographic region, comorbidities, and HCRU during the pre-index period were adjusted by 1:1 propensity score (PS) matching (PSM). RESULTS: Overall, opioids were prescribed in 56% of patients in ED, and 71% in inpatient setting. After excluding patients with pre-index opioid use (N=163), among 27,599 eligible patients, 68% (RxOP: N=18,819) were prescribed opioids, and 32% (NoRxOP: N=8,780) were not. The majority of patients (96%, N=18,031) were prescribed immediate-release opioids and 4% (N=788) extended-release opioids (LAO use slightly higher in ED versus inpatient, 6.5% versus 3.7%, p<0.01). Among the 5099 PS matched patients, adjusted results showed that RxOP patients had more inpatient (1.58 vs. 0.36, p<0.01), physician (10.17 vs.8.96, p<0.01) and ED visits (1.12 vs. 0.67, p<0.01) than NoRxOP patients in the follow-up period. RxOP users had twice the total healthcare costs ($49,766 vs. $19,875, p<0.01) than NoRxOp patients. CONCLUSIONS: A large percentage of patients are prescribed opioids for the first time during ED/inpatient visits and incur a significantly higher resource use and economic burden than those who are not.
Conference/Value in Health Info
2012-06, ISPOR 2012, Washington, D.C., USA
Value in Health, Vol. 15, No. 4 (June 2012)
Code
PMH24
Topic
Economic Evaluation
Topic Subcategory
Cost-comparison, Effectiveness, Utility, Benefit Analysis
Disease
Mental Health